Evidence map›Paper›PMID 32697968›Full record

ArticleCell2020

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.

Bette Korber, Will M Fischer, Sandrasegaram Gnanakaran, Hyejin Yoon, James Theiler, Werner Abfalterer, Nick Hengartner, Elena E Giorgi, Tanmoy Bhattacharya, Brian Foley and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2,574 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,574citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2,574 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2,514 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Bette KorberTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87545, USA. Electronic address: btk@lanl.gov.
Will M FischerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Sandrasegaram GnanakaranTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Hyejin YoonTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
James TheilerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Werner AbfaltererTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Nick HengartnerTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Elena E GiorgiTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Tanmoy BhattacharyaTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Brian FoleyTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Kathryn M HastieLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Matthew D ParkerSheffield Biomedical Research Centre & Sheffield Bioinformatics Core, University of Sheffield, Sheffield S10 2HQ, UK.
David G PartridgeSheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK.
Cariad M EvansSheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK.
Timothy M FreemanSheffield Biomedical Research Centre & Sheffield Bioinformatics Core, University of Sheffield, Sheffield S10 2HQ, UK.
Thushan I de SilvaSheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK; Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield S10 2RX, UK.
Sheffield COVID-19 Genomics Group
Charlene McDanalDuke Human Vaccine Institute & Department of Surgery, Durham, NC 27710, USA.
Lautaro G PerezDuke Human Vaccine Institute & Department of Surgery, Durham, NC 27710, USA.
Haili TangDuke Human Vaccine Institute & Department of Surgery, Durham, NC 27710, USA.
Alex Moon-WalkerLa Jolla Institute for Immunology, La Jolla, CA 92037, USA; Program in Virology, Harvard University, Boston, MA 02115, USA; Department of Molecular Microbiology, Washington University in Saint Louis, St. Louis, MO 63130, USA.
Sean P WhelanDepartment of Molecular Microbiology, Washington University in Saint Louis, St. Louis, MO 63130, USA.
Celia C LaBrancheDuke Human Vaccine Institute & Department of Surgery, Durham, NC 27710, USA.
Erica O SaphireLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
David C MontefioriDuke Human Vaccine Institute & Department of Surgery, Durham, NC 27710, USA.

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9M
Training in Immunological MechanismsT32AI125179 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2016 to 2025
$3.1M
NIAID NIH HHS P30 AI036214NIAID NIH HHS R37 AI150590NIAID NIH HHS T32 AI125179Wellcome Trust
6 · The paper itself

Abstract

A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies revealed a recurrent pattern of G614 increase at multiple geographic levels: national, regional, and municipal. The shift occurred even in local epidemics where the original D614 form was well established prior to introduction of the G614 variant. The consistency of this pattern was highly statistically significant, suggesting that the G614 variant may have a fitness advantage. We found that the G614 variant grows to a higher titer as pseudotyped virions. In infected individuals, G614 is associated with lower RT-PCR cycle thresholds, suggestive of higher upper respiratory tract viral loads, but not with increased disease severity. These findings illuminate changes important for a mechanistic understanding of the virus and support continuing surveillance of Spike mutations to aid with development of immunological interventions.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19Epidemiological MonitoringGenetic FitnessGenetic VariationGeographic Information SystemsHospitalizationHumansPandemicsPhylogenyPneumonia, ViralRespiratory SystemSARS-CoV-2Severity of Illness IndexSpike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodyCOVID-19diversityevolutioninfectivityneutralizationPCR cycle thresholdpseudovirusSARS-CoV-2Spike

Identifiers

PMID32697968
PMCPMC7332439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.